Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$9.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for assessing the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and generate sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $10 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs in oncology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's focus on innovative cancer therapies. However, past earnings misses have created some skepticism.

Bull Case

If Nuvalent can demonstrate progress in its clinical trials and show improved financial metrics, it could attract more investor interest and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its drug pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Nuvalent's clinical trials?

Updates on clinical trials can significantly influence investor confidence and stock performance.

How does the company plan to address its recent earnings misses?

Management's strategy for improving financial performance will be critical for restoring investor trust.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's pipeline, especially if there are positive updates on clinical trials that haven't been fully priced in.

Supporting Evidence

The stock has shown significant volatility in past earnings, suggesting that current expectations may not capture the full potential upside.

Options are pricing a 3.87% move, but historical data shows that the stock has moved more than this in the past.

The lack of recent peer reports may indicate that the market is not fully aware of the competitive landscape.

Key Risk

If clinical trial updates exceed expectations, it could lead to a significant re-evaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to show tangible advancements in its drug pipeline and improve financial metrics.

Bull Confirmed If

Demonstrating significant progress in clinical trials could validate the bull case.

Bear Confirmed If

Further earnings misses or lack of progress in drug development would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.87%

Historical Avg

±3.9%

In line with history

The options market is pricing in a modest move, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by around 3.9%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses expectations again, history suggests a potential decline of about 1.06%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that could enhance the drug pipeline.
4Insights into market demand for Nuvalent's therapies.
5Future guidance on revenue and EPS expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for assessing the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and generate sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's focus on innovative cancer therapies. However, past earnings misses have created some skepticism.

Bull Case

If Nuvalent can demonstrate progress in its clinical trials and show improved financial metrics, it could attract more investor interest and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its drug pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Nuvalent's clinical trials?

Updates on clinical trials can significantly influence investor confidence and stock performance.

How does the company plan to address its recent earnings misses?

Management's strategy for improving financial performance will be critical for restoring investor trust.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's pipeline, especially if there are positive updates on clinical trials that haven't been fully priced in.

Supporting Evidence

The stock has shown significant volatility in past earnings, suggesting that current expectations may not capture the full potential upside.

Options are pricing a 3.87% move, but historical data shows that the stock has moved more than this in the past.

The lack of recent peer reports may indicate that the market is not fully aware of the competitive landscape.

Key Risk

If clinical trial updates exceed expectations, it could lead to a significant re-evaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to show tangible advancements in its drug pipeline and improve financial metrics.

Bull Confirmed If

Demonstrating significant progress in clinical trials could validate the bull case.

Bear Confirmed If

Further earnings misses or lack of progress in drug development would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.87%

Historical Avg

±3.9%

In line with history

The options market is pricing in a modest move, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by around 3.9%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses expectations again, history suggests a potential decline of about 1.06%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that could enhance the drug pipeline.
4Insights into market demand for Nuvalent's therapies.
5Future guidance on revenue and EPS expectations.